Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature
© Varghese et al. 2016
Received: 27 December 2015
Accepted: 12 February 2016
Published: 24 February 2016
Abdominal leiomyosarcoma arising from the mesentery is a rare malignancy. It is an aggressive entity with an overall 5 year survival rate between 20 and 30 %. Surgical resection is the cornerstone of primary treatment and may be curative for localized disease. However, patients often develop intra-abdominal relapse and/or metastatic disease. If surgical resection is not feasible, palliative chemotherapy is the treatment of choice. However, there are no clear guidelines regarding chemotherapy; neither in the adjuvant nor advanced setting.
We present a 40 year-old woman, with a mesenteric leiomyosarcoma, who underwent radical tumor resection and did not receive adjuvant oncological therapy. Three months postoperatively, she developed metastatic disease to the lungs and liver. After multidisciplinary assessment she received an unconventional histological-subtype-tailored chemotherapy comprising 3–4 regimens. Initially, there was a decrease both in number and size of metastases. Ultimately, an almost complete radiological response was seen. Subsequent surgical resection and radiofrequency ablation of residual metastatic foci in the liver and lung brought her into complete clinical remission. She is presently tumor free, 36 months following diagnosis of metastatic disease.
To our knowledge, this is the first report of a patient with metastatic mesenteric leiomyosarcoma who is in complete clinical and radiological long-term remission following very aggressive multimodal treatment; including intense poly-drug chemotherapy and without any demonstrable long-term side effects. Given the rarity of mesenteric leiomyosarcoma and lack of guidelines regarding oncological therapy, we suggest that multimodal therapy including aggressive chemotherapy, guided by a multidisciplinary team, is essential to achieve an optimal outcome.
KeywordsLeiomyosarcoma Mesenteric Abdominal Histological-subtype Chemotherapy Metastases Multimodal
Leiomyosarcoma (LMS) represents between 10 and 20 % of all newly diagnosed soft tissue sarcomas . It is classified based on anatomical site of origin, a factor that is important for outcome and prognosis . Abdominal LMS is highly aggressive with an overall 5 year survival rate between 20 and 30 % . Although histologically similar, the different anatomic variants of abdominal LMS have varying clinical behaviour and differ in prognosis . Surgical resection is the cornerstone of curative treatment for localized disease if adequate margins are obtained [1, 5]. However, this is often not possible due to anatomical restrictions and large tumor size at diagnosis. Moreover, LMS tends to metastasize, most commonly to the lungs and liver. Unfortunately, there are no clear guidelines regarding the role of oncological treatment; neither in the primary nor metastatic setting . In fact, almost all patients with metastatic disease are considered incurable and, thus, offered only palliative treatment.
Here, we present a patient with an abdominal LMS, specifically a mesenteric LMS. This is a rare malignancy, with only a few cases reported in the literature [6–9]. The LMS was surgically resected with an R0 margin and no adjuvant oncological therapy was given. Unfortunately, the patient developed metastatic disease both to the liver and lungs. Histological evaluation of metastases revealed a highly malignant, pleomorphic sarcoma that resembled her primary tumor, but was not morphologically identical. It was categorized as dedifferentiated LMS [3, 10]. An aggressive multimodal therapeutic strategy was chosen, including staggered intensive chemotherapy tailored to the histological-subtype of the metastasis . Presently, she is in complete clinical remission about 36 months following diagnosis of metastatic disease and without any demonstrable long-term side effects from chemotherapy.
Our patient is a 40 year old woman who had no significant medical history except for an appendectomy when she was 20 years-old. She presented with a two-month history of left sided abdominal pain accompanied by abdominal discomfort and distention. Additionally, she suffered from nausea and vomiting without any changes in stool pattern.
About two weeks later, the patient was operated via a midline laparotomy. The tumor, which was partly adherent to the sigmoid mesocolon, was removed en bloc together with 15 cm of small intestine and colon. An antiperistaltic side-to-side-anastomosis was established at the splenic flexure as well as a small intestinal anastomosis about 120 cm proximal to the ileocaecal valve. No intraperitoneal metastases were seen, but tumor perforation to the peritoneal cavity and resulting bloody ascites was documented perioperatively. Despite this high risk for tumor relapse, no adjuvant therapy was given to the patient in line with guidelines regarding adjuvant therapy for abdominal LMS .
Five months after surgery for metastatic disease, the patient developed abdominal pain and constipation. CT of the abdomen and thorax revealed only postoperative changes. Moreover, upper and lower endoscopy was unremarkable. A contrast study showed no pathology, only stenosis of the small intestine, which was dilatated, and the patient showed symptomatic relief after laxative therapy. The patient is presently in clinical remission, 36 months following diagnosis of metastatic disease.
Mesenteric LMS was first described in 1963  and is most likely derived from the smooth muscle cells of blood vessels in the mesentery . It is an aggressive disease and approximately half of all patients will develop distant metastases despite adequate local control . The overall 5 year survival rate is only 20–30 % , partly because mesenteric LMS often remains undetected until late in the course of disease development, due to the large available space of the abdominal cavity. As in the case of our patient, abdominal distension and discomfort are common presenting symptoms . Additionally, altered bowel movements and weight loss are also seen. Blood tests are non-specific but may reveal anaemia  and elevated acute phase proteins. Radiological assessment is mandatory for preoperative evaluation of tumor location, dimensions and relation to adjacent structures. Definitive diagnosis is based on histopathology.
Treatment of abdominal LMS
Surgery is the cornerstone of treatment and is the only therapeutic modality proven to provide cure . However, complete resection is often difficult due to large tumor size at presentation and recent studies have shown that resection margins may be the only significant predictor of local recurrence [4, 15]. Moreover, complete primary surgical resection is critical for achieving the best overall outcome . Other factors include tumor depth, histological grade, and metastasis at presentation [15, 17]. The role of adjuvant chemotherapy in localized disease is not established and therefore is not standard treatment . It can be proposed to high-risk patients, after multidisciplinary assessment or within clinical trials. In keeping with current guidelines, our patient did not receive adjuvant treatment.
When our patient developed metastatic disease, a core needle biopsy of a liver metastasis was obtained. Though the biopsy material was limited, a highly malignant tumor, displaying only large pleomorphic cells similar to the cells focally present in the primary tumor, was seen. This may suggest a histological-subtype that had evolved into a dedifferentiated phenotype compared to the primary tumor. This was the reason for choosing to add ifosfamide, rather than dacarbazine, to the initial regimen . Such biological heterogeneity is documented between primary and metastatic disease in a number of malignancies . Patients with pleomorphic or dedifferentiated LMS have a particularly poor prognosis, with a metastatic rate of 89 % .
The choice of chemotherapeutic agents depend on several factors including histological-subtype, age, co-morbidity and expected tolerance of side effects. Our present knowledge regarding chemotherapy of LMS is mainly based on non-randomized phase II studies or retrospective case series . Furthermore, the rarity and heterogeneity of soft tissue sarcomas, as well as the high variability of patient characteristics, chemotherapeutic regimens, histological and molecular subtypes (early trials might even have included GIST patients), the variable follow-up and differing definitions of end points all preclude the available evidence of chemotherapeutic effectiveness.
Despite the paucity of randomized trials, anthracyclines, either as a single-or-multi-agent chemotherapy, are the first-line of treatment for abdominal LMS , according to the ESMO-guidelines. Moreover, depending on the histological-subtype, doxorubicin and dacarbazine (for a purely LMS)  or doxorubicin and ifosfamide (for malignancies with a pleomorphic cellular component)  have been advocated. Second-line chemotherapeutic agents recommended include (1) standard ifosfamide or high-dose ifosfamide (around 14 g/m2) , (2) a combination of gemcitabine and docetaxel  (which showed improved progression free survival and overall survival than gemcitabine alone) , (3) a combination of dacarbazine and gemcitabine  and (4) trabectedin . The rationale for giving the patient such intense and sequential chemotherapy has previously been shown to be successful  in achieving a maximal radiological and clinical response. It has also been reported to improve long-term survival . We chose not to use trabectedin and pazopanib as there is not much experience with these drugs in a curative treatment setting.
For advanced metastatic disease, surgery or radiofrequency ablation is usually not the treatment of choice, but may be considered in selected cases where the number of metastatic foci are few and amenable to intervention. Given the remarkable response of our patient to chemotherapy, we decided to remove remaining lesions in the lung and liver using surgical resection and radiofrequency ablation with the hope of achieving long-term, complete clinical remission . The rational for such an approach is that the smallest lesions, including micrometastases, may have been completely eradicated by the chemotherapy. Hence, removing the larger metastases, which may still contain foci of viable sarcoma cells, eliminates the nidus for subsequent relapse. While the degree of response to preoperative chemotherapy has not been demonstrated to influence post-resection survival, largely due to small sample size, the progression of disease prior to resection is a known adverse prognostic factor . The presence of disease outside the chest has been considered a contraindication to resection of pulmonary metastases. More recently, however, it has been shown that resection of pulmonary and extrapulmonary metastases results in disease-free survival and overall survival, similar to that seen in patients who undergo resection of metastases limited to the lungs .
To our knowledge, this is the first report of a patient with metastatic mesenteric LMS who developed complete clinical and radiological remission without any demonstrable long-term side effects from chemotherapy, after receiving multimodal therapy including an unconventional histological-subtype-tailored chemotherapy comprising 3–4 regimens, surgical resection and radiofrequency ablation of metastatic foci. Given the rarity of mesenteric leiomyosarcoma and lack of guidelines regarding oncological therapy, we suggest that multimodal therapy including aggressive histological-subtype tailored chemotherapy can result in complete remission under the guidance of a multidisciplinary team.
Study Concept and Study Design: RB, KSH, OB. Data Acquisition: KSH, MV, IL, AMW. Quality control of data: KSH, OB. Data analysis and interpretation: KSH, OB, MV. Manuscript preparation: MV. Manuscript editing: RB, KSH, OB. Manuscript review: All authors. All authors read and approved the final manuscript.
We would like to acknowledge gastrointestinal surgeons T. Hølmebakk and S. Stoldt and thoracic surgeon L. Jørgensen.
Availability of data and materials
The dataset supporting the conclusion of this article is presented in this manuscript.
The authors declare that they have no competing interests.
Written informed consent was obtained from the patient.
Ethics, approval and consent
The research on this case report was conducted in accordance with the Declaration of Helsinki and in accordance with the guidelines at The Norwegian Radium Hospital.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin North Am. 2013;27(5):957–74.View ArticlePubMedGoogle Scholar
- Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, Casali PG, Gronchi A. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. Ann Surg Oncol. 2012;19(2):511–8.View ArticlePubMedGoogle Scholar
- Hashimoto H, Tsuneyoshi M, Enjoji M. Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases. J Surg Oncol. 1985;28(3):177–86.View ArticlePubMedGoogle Scholar
- Bathan AJ, Constantinidou A, Pollack SM, Jones RL. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013;25(4):384–9.View ArticlePubMedGoogle Scholar
- ESMO. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):iii102–12.Google Scholar
- Kim KJ, Lee WS, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Metastatic cutaneous leiomyosarcoma from primary neoplasm of the mesentery. Int J Dermatol. 2001;40(8):527–9.View ArticlePubMedGoogle Scholar
- Koczkowska M, Lipska BS, Grzeszewska J, Limon J, Biernat W, Jassem J. Primary leiomyosarcoma of the mesentery in two sisters: clinical and molecular characteristics. Pol J Pathol. 2013;64(1):59–63.View ArticlePubMedGoogle Scholar
- Natarajan A, Rudresh HK, D’Souza RE, Lahoti NG. Primary leiomyosarcoma of jejunal mesentery: a rare case. Trop Gastroenterol. 2000;21(1):30–2.PubMedGoogle Scholar
- Simonovich CJ, Hardman JM, Navin JJ, Jacobs J, Fergusson N. An unusual abdominal tumor–leiomyosarcoma of the mesentery: a case report. Hawaii Med J. 2006;65(1):18–20.PubMedGoogle Scholar
- Nicolas MM, Tamboli P, Gomez JA, Czerniak BA. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol. 2010;41(5):663–71.View ArticlePubMedGoogle Scholar
- Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21(Suppl 7):vii270–6.PubMedGoogle Scholar
- Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, Hofstetter W, Walsh GL, Benjamin R, Pollock R, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009;88(3):877–84.View ArticlePubMedGoogle Scholar
- Yannopoulous K, Stout AP. Primary solid tumors of the mesentery. Cancer. 1963;16:914–27.View ArticleGoogle Scholar
- Penel N, Italiano A, Isambert N, Bompas E, Bousquet G, Duffaud F. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol. 2010;21(6):1361–5.View ArticlePubMedGoogle Scholar
- Abraham JA, Weaver MJ, Hornick JL, Zurakowski D, Ready JE. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. J Bone Joint Surg Am. 2012;94(8):736–44.View ArticlePubMedGoogle Scholar
- Nagarsheth NP, Nicastri DG, Kashani M, Fried K. Complete surgical resection of a 40-cm leiomyosarcoma of the large bowel mesentery. J Surg Educ. 2007;64(3):162–4.View ArticlePubMedGoogle Scholar
- Italiano A, Lagarde P, Brulard C, Terrier P, Lae M, Marques B, Ranchere-Vince D, Michels JJ, Trassard M, Cioffi A, et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. Clin Cancer Res. 2013;19(5):1190–6.View ArticlePubMedGoogle Scholar
- Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.View ArticlePubMedGoogle Scholar
- Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.View ArticlePubMedGoogle Scholar
- Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le CA, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.View ArticlePubMedGoogle Scholar
- Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called “MFH”) in adults. J Surg Oncol. 2008;97(4):330–9.View ArticlePubMedGoogle Scholar
- Le CA, Antoine E, Spielmann M, Le CT, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600–8.Google Scholar
- Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824–31.View ArticlePubMedGoogle Scholar
- Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755–63.View ArticlePubMedGoogle Scholar
- Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A, Gomez-Espana A, Fra J, Cruz J, Poveda A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):2528–33.View ArticlePubMedGoogle Scholar
- Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le CA, Sanfilippo R, Casieri P, Collini P, Dileo P, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602.View ArticlePubMedGoogle Scholar
- Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22(9):1706–12.View ArticlePubMedGoogle Scholar
- Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Saeter G, Jorgensen LH, Hall KS. Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma—a predictor of outcome? Acta Oncol. 2014;53(9):1180–7.View ArticlePubMedGoogle Scholar
- Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg. 2002;14(1):35–44.View ArticlePubMedGoogle Scholar
- Stephens EH, Blackmon SH, Correa AM, Roth JA, Rice DC, Hofstetter W, Benjamin R, Mehran R, Swisher SG, Walsh GL, et al. Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011;212(5):821–6.View ArticlePubMedGoogle Scholar